Defining response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 32, Issue 1, 2005, Pages 6-10

  Hider, Samantha L ^a   Bruce, Ian N ^b   Silman, Alan J ^a   Symmons, Deborah P M ^b  

^a Dept of Rheum Disease Epidemiology ^*

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PLACEBO;

CLINICAL TRIAL; DISEASE ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; HUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; PROGNOSIS; RHEUMATOLOGY; TREATMENT OUTCOME;

EID: 11844269893     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (25)

1. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
2. Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44.
3. Jenkins JK, Hardy KJ. Biological modifier therapy for the treatment of rheumatoid arthritis. Am J Med Sci 2002;323:197-205.
4. National Institute for Clinical Excellence. Guidance on the use of etanercept and infliximab for rheumatoid arthritis. London: NICE Technology Appraisal; 2002:NICE 36. Internet. [cited July 21, 2004] Available from: http://www.nice.org.uk/page.aspx?o=35993.
5. Hider SL, Buckley C, Silman A, Symmons D, Bruce IN. Factors influencing response to disease modifying drugs in patients with rheumatoid arthritis. J Rheumatol 2005;32:11-6.
6. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994-1002.
7. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
8. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35-45.
9. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308-15.
10. Paulus HE. Defining remission in rheumatoid arthritis: what is it? Does it matter? J Rheumatol 2004;31:1-4.
11. Paulus HE, Egger MJ, Ward JR, Williams HJ. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum 1990;33:477-84.
12. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
13. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40.
14. Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998;41:1564-70.
15. Pincus T, Stein CM. ACR 20: clinical or statistical significance? Arthritis Rheum 1999;42:1572-6.
16. van Gestel AM, Prevoo ML, 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
17. van der Heijde DM, 't Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
18. van der Heijde DM, van 't HM, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
19. Prevoo ML, 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
20. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
21. Prevoo ML, van Gestel AM, van THM, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996;35:1101-5.
22. Schiff M, Weaver E, Keystone E, Moreland I, Spencer-Green, G. Comparison of ACR response, numeric ACR and ACR AUC as measures of clinical improvement in RA [abstract]. Arthritis Rheum 1999;42 Suppl: s81.
23. Schiff M. A rationale for the use of summary measurements for the assessment of the effects of rheumatoid arthritis therapies. Clin Ther 2003;25:993-1001.
24. van Riel PL, van Gestel AM. Area under the curve for the American College of Rheumatology improvement criteria: a valid addition to existing criteria in rheumatoid arthritis? Arthritis Rheum 2001;44:1719-21.
25. Hurst S, Kallan MJ, Wolfe FJ, Fries JF, Albert DA. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects. J Rheumatol 2002;29:1639-45.